Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Avitinib in Patients With Advanced Non Small Cell Lung Cancer Who Progressed on Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Agent

Trial Profile

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Avitinib in Patients With Advanced Non Small Cell Lung Cancer Who Progressed on Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Agent

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Nov 2016

At a glance

  • Drugs Avitinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Most Recent Events

    • 21 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 21 Nov 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.
    • 11 Oct 2016 Results (n=51, as of 5th May 2016) presented at the 41st European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top